hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06325631, orgStudyIdInfo id: Ankara City Hospital Bilkent, briefTitle: Comparative Evaluation of the Results of Facet Joint Injections, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-01-02, primaryCompletionDateStruct date: 2024-03-31, completionDateStruct date: 2024-04-30, studyFirstPostDateStruct date: 2024-03-22, lastUpdatePostDateStruct date: 2024-03-22, sponsorCollaboratorsModule leadSponsor name: Oznur Uzun, class: OTHER, descriptionModule briefSummary: Low back pain affects 60 to 90% of the total population. It is one of the most common causes of disability in adults. Low back pain can be originated from a wide variety of structures, and the facet joint is one of these structures. It is thought that 21 to 41% of low back pain originates from the facet joint. A wide variety of conservative treatments, including intra-articular injections, are used to treat low back pain originating from the facet joint. However, there is still no consensus on the most effective treatment method. With appropriate patient selection, facet joint injections can provide significant improvements in patients' pain scores. After Goldthwait defined the facet joint concept in 1911, Ghormley defined facet joint syndrome in 1933. The source of pain in 40-50% of patients is the lumbar facet joints. Innervation of the lumbar facet joints is provided by the medial branches of the dorsal roots of the spinal nerves. In 1975, Shealy described the coagulation of the articular nerve support of the spinal facet joints with the radiofrequency method. These methods have been further developed over time. The results of facet joint injections are satisfactory in well-selected patient groups. It has been shown that intra-articular steroid injection to the facet joint is superior to systemic steroid use in patients with low back pain. In this study, it was aimed to methodically compare the facet joint injections applied to patients diagnosed with facet syndrome in the outpatient clinic of the Physical Therapy and Rehabilitation Hospital in terms of patient pain scores, application time, effort spent and patient anxiety. Intra-articular injections will be performed under by fluoroscopy or ultrasound guidance or anatomic location., conditionsModule conditions: Low Back Pain, Mechanical, conditions: Facet Syndrome of Lumbar Spine, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: INVESTIGATOR, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Intra-articular injection to lumbar facet joint, outcomesModule primaryOutcomes measure: Visual Analogue Scale, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: Ankara Bilkent Şehir Hastanesi, status: RECRUITING, city: Ankara, country: Turkey, contacts name: Öznur UZUN, MD, role: CONTACT, phone: +905052912734, email: soznuruzuns@gmail.com, geoPoint lat: 39.91987, lon: 32.85427, hasResults: False
protocolSection identificationModule nctId: NCT06325618, orgStudyIdInfo id: 1-10-72-138-23, briefTitle: Lymphedema, Low-grade Inflammation and the Vasculature in Turner Syndrome, acronym: TSCOR_V, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-08, primaryCompletionDateStruct date: 2027-08, completionDateStruct date: 2027-08, studyFirstPostDateStruct date: 2024-03-22, lastUpdatePostDateStruct date: 2024-03-22, sponsorCollaboratorsModule leadSponsor name: University of Aarhus, class: OTHER, collaborators name: Aarhus University Hospital, descriptionModule briefSummary: 100 women with karyotype verified TS, previously examined at 4 study visits during a 19-year period will be asked to participate in a 5th study visit. Healthy age-matched females will be included as controls in a ratio 2:1.The aim is to examine and quantify the cardiovascular and lymphatic system in women with TS. The investigators will study a possible causal mechanism between the known pathologic phenotype and alterations in these systems to understand, prevent or treat the life-threatening complications in TS., conditionsModule conditions: Turner Syndrome, conditions: Cardiovascular Diseases, conditions: Lymphedema, conditions: Inflammation, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 150, type: ESTIMATED, armsInterventionsModule interventions name: No intervention other than obtaining biopsies, interventions name: Indocyanine green (ICG), outcomesModule primaryOutcomes measure: Grade dysfunction of clinical and subclinical lymphedema using Indocyanine Green Lymphography and Magnetic Resonance Lymphangiography., primaryOutcomes measure: Detecting low-grade inflammation in Turner Syndrome preforming FDG-PET/CT-scans to locate low grade inflammation., primaryOutcomes measure: Heat maps of the distribution of wall shear stress in the aorta, secondaryOutcomes measure: MRI evaluation and description of vascular abnormalities in Turner Syndrome, secondaryOutcomes measure: Cardiac MRI to evaluate function, secondaryOutcomes measure: Cardiac MRI to evaluate fibrosis of the myocardium, secondaryOutcomes measure: Mapping DNA-methylations patterns in multiple tissues, secondaryOutcomes measure: Immunologic changes in Turner Syndrome, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 100 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Aarhus University Hospital, status: RECRUITING, city: Aarhus N, zip: 8200, country: Denmark, contacts name: Line Balsby, MD, role: CONTACT, phone: +4520461203, email: libals@clin.au.dk, contacts name: Claus Gravholt, MD, Prof., role: CONTACT, geoPoint lat: 56.15674, lon: 10.21076, hasResults: False
protocolSection identificationModule nctId: NCT06325605, orgStudyIdInfo id: GRYY-LL-KJ2022-064, briefTitle: Efficacy and Safety of Bifidobacterium Combined With High-frequency Transcranial Magnetic Stimulation in the Treatment of Adolescent Depression, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-03-01, primaryCompletionDateStruct date: 2022-10-31, completionDateStruct date: 2022-10-31, studyFirstPostDateStruct date: 2024-03-22, lastUpdatePostDateStruct date: 2024-03-22, sponsorCollaboratorsModule leadSponsor name: Zhen-Hong Hu, class: OTHER, descriptionModule briefSummary: A total of 100 patients with adolescent depression who were admitted to our hospital between March 2022 and October 2022 were selected. On the basis of double blinding, these patients were randomly divided into the observation group(n=50) and the control group(n=50) using a random number table. 5S management method was used in the whole process of treatment to improve the hospital environment, increase the work efficiency and reduce the occurrence of cross infection through the effective implementation of the five steps of sort(Seiri), set in order(Seiton), shine (Seiso), standardize(Seiketsu) and sustain(Shitsuke)., conditionsModule conditions: Adolescent Depression, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, enrollmentInfo count: 100, type: ACTUAL, armsInterventionsModule interventions name: Bifidobacterium, interventions name: High-frequency rTMS, interventions name: Escitalopram Oxalate, outcomesModule primaryOutcomes measure: HAMD-24 scores, primaryOutcomes measure: TNF-α, primaryOutcomes measure: IL-1β, primaryOutcomes measure: IL-6, primaryOutcomes measure: DA, primaryOutcomes measure: 5-HT, primaryOutcomes measure: COR, primaryOutcomes measure: Serum miR-16, primaryOutcomes measure: Serum miR-195, eligibilityModule sex: ALL, minimumAge: 13 Years, maximumAge: 18 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: Tangshan Workers' Hospital, city: Tangshan, state: Hebei, zip: 063003, country: China, geoPoint lat: 39.63333, lon: 118.18333, hasResults: False
protocolSection identificationModule nctId: NCT06325592, orgStudyIdInfo id: REHSIL2023V1.1, briefTitle: Association Between Surgical Timing and Route of Total Hysterectomy After LEEP and Perioperative Risk in Patients With Cervical HSIL, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-10-01, primaryCompletionDateStruct date: 2024-03-01, completionDateStruct date: 2024-03-01, studyFirstPostDateStruct date: 2024-03-22, lastUpdatePostDateStruct date: 2024-03-22, sponsorCollaboratorsModule leadSponsor name: Sichuan Cancer Hospital and Research Institute, class: OTHER, descriptionModule briefSummary: This study aimed to analyze perioperative information in patients with high-grade squamous intraepithelial lesion (HSIL) undergoing total hysterectomy (TH), offering insights into optimal surgery timing, selecting the operation path, and enhancing surgical operation details., conditionsModule conditions: High-Grade Squamous Intraepithelial Lesions, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 826, type: ACTUAL, armsInterventionsModule interventions name: surgical timing and operation path, outcomesModule primaryOutcomes measure: Postoperative fever, primaryOutcomes measure: Postoperative therapeutic use of antibiotics, secondaryOutcomes measure: Postoperative complications, secondaryOutcomes measure: Postoperative hospitalization days, secondaryOutcomes measure: Postoperative hemoglobin, secondaryOutcomes measure: Postoperative white blood cell count, secondaryOutcomes measure: Postoperative erythrocyte count, secondaryOutcomes measure: Postoperative albumin number, secondaryOutcomes measure: Postoperative CRP value, eligibilityModule sex: FEMALE, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Sichuan Cancer Hospital and Research Institute, city: Chengdu, state: Sichuan, zip: 610000, country: China, geoPoint lat: 30.66667, lon: 104.06667, hasResults: False
protocolSection identificationModule nctId: NCT06325579, orgStudyIdInfo id: AA29411356, briefTitle: Immersive Virtual Reality for Dysphagia, acronym: IVRys, statusModule overallStatus: COMPLETED, startDateStruct date: 2021-05-24, primaryCompletionDateStruct date: 2023-02-28, completionDateStruct date: 2023-03-31, studyFirstPostDateStruct date: 2024-03-22, lastUpdatePostDateStruct date: 2024-03-25, sponsorCollaboratorsModule leadSponsor name: Sheffield Hallam University, class: OTHER, descriptionModule briefSummary: People who have suffered a stroke are at high risk of suffering from oropharyngeal dysphagia with long and intensive exercise programmes. Early access to treatment and engaging therapies is very important for recovery. Immersive virtual reality technology presents an innovative treatment that could help patients improve swallowing. The aim of this study is to improve swallowing in stroke patients using two bespoke immersive virtual reality treatment with real-time feedback. The study consisted in a small feasibility study with stroke patients suffering dysphagia (n = 6, aged of 39 to 80 (M=71.17, SD=15.94). Results obtained through interviews with the patients indicated no discomfort reported during the game. All patients reported enjoying the game and feeling engaged and immersive and four out of six patients reported that they would like to use it every day as part of their Speech and Language therapy. The SALT assistant involved in the study stated that the system had the potential to encourage patients to swallow, being more functional than conventional speech therapy. She identified improvements needed for a better functioning of the VR rehabilitation system for Dysphagia. In a future study, wireless headsets will be used, without a laptop, and it will be important to improve the reliability and design of the strain gauge or innovate in the use of a different technology., conditionsModule conditions: Virtual Reality, conditions: Dysphagia, conditions: Treatment Compliance, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: DEVICE_FEASIBILITY, maskingInfo masking: NONE, enrollmentInfo count: 6, type: ACTUAL, armsInterventionsModule interventions name: Immersive Virtual Reality for Dysphagia Treatment, outcomesModule primaryOutcomes measure: Feasibility of the system. Semi-structure Interviews with patients and staffs. Qualitative outcomes., primaryOutcomes measure: Feasibility of the system. Semi-structure Interviews with patients. Quantitative outcomes., eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Sheffield Hallam University, city: Sheffield, state: South Yorkshire, zip: S1 2NU, country: United Kingdom, geoPoint lat: 53.38297, lon: -1.4659, hasResults: False
protocolSection identificationModule nctId: NCT06325566, orgStudyIdInfo id: MSB-DR004, briefTitle: Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain, acronym: HyaluronicAcid, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2026-08, completionDateStruct date: 2027-08, studyFirstPostDateStruct date: 2024-03-22, lastUpdatePostDateStruct date: 2024-03-22, sponsorCollaboratorsModule leadSponsor name: Mesoblast, Ltd., class: INDUSTRY, descriptionModule briefSummary: The primary purpose of this study is to evaluate the efficacy of rexlemestrocel-L+HA compared to control in reducing low back pain at 12 months post-treatment and safety of a single injection of rexlemestrocel-L+HA injected into a lumbar intervertebral disc compared to control through 12 months post-treatment., conditionsModule conditions: Degenerative Disc Disease, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 300, type: ESTIMATED, armsInterventionsModule interventions name: Rexlemestrocel-L + HA mixture, interventions name: Saline, outcomesModule primaryOutcomes measure: Mean Change From Baseline in Daily Average Low Back Pain at 12 Months Post-treatment Based on Visual Analog Scale (VAS) Score, primaryOutcomes measure: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs), secondaryOutcomes measure: Percentage of 30% VAS Pain Responders at 12 Months Post-treatment, secondaryOutcomes measure: Mean Change From Baseline in Quality of Life Measured by Euroqol-5D (EQ-5D) Index Score at 12 Months Post-treatment, secondaryOutcomes measure: Percentage of Minimal Pain Responders at 12 Months Post-treatment, secondaryOutcomes measure: Mean Change From Baseline in Function as Measured by Oswestry Disability Index (ODI) Questionnaire Score at 12 Months Post-treatment, secondaryOutcomes measure: Percentage of Participants With 30% VAS and 10-point ODI Treatment Success at 12 Months Post-treatment, secondaryOutcomes measure: Percentage of Participants Who Ceased Opioid Usage at 24 Months Post-treatment, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06325553, orgStudyIdInfo id: 022_2566, briefTitle: Incidence of Platelet Refractoriness in Adult Acute Leukemia Patients Receiving Prestorage Filtered Blood and Comparing With Historical Control, acronym: PTR, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-30, primaryCompletionDateStruct date: 2025-03-30, completionDateStruct date: 2026-03-30, studyFirstPostDateStruct date: 2024-03-22, lastUpdatePostDateStruct date: 2024-03-22, sponsorCollaboratorsModule leadSponsor name: Siriraj Hospital, class: OTHER, descriptionModule briefSummary: This research project is evaluate the incidence of platelet refractoriness in newly diagnosed acute leukemia patients receiving PFB during induction and first consolidation phase chemotherapy compared to 2 historical control groups which are patients receiving non-leukocyte depleted blood product group and leukocyte depleted blood product group and demonstrate cost-effectiveness of using blood products with filtered process to prevent clinical platelet refractoriness compare with using HLA-matched blood products after platelet refractoriness occurs, conditionsModule conditions: Platelet Refractoriness in Adult Acute Leukemia, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: PROSPECTIVE, enrollmentInfo count: 252, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Descriptive statistics, primaryOutcomes measure: Inferential statistics, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Siriraj hospital, status: RECRUITING, city: Bangkok, zip: 10700, country: Thailand, contacts name: weerapat Owattanapanich, MD, role: CONTACT, phone: 0891081963, email: weerapato36733@gmail.com, contacts name: Phakaporn Chamweha, DR, role: CONTACT, phone: 06855156615, email: phakaporn.cham@gmail.com, geoPoint lat: 13.75398, lon: 100.50144, hasResults: False
protocolSection identificationModule nctId: NCT06325540, orgStudyIdInfo id: pulpcapping, briefTitle: Clinical Success of Indirect Pulp Capping: 1-Year Follow-Up, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-01-01, primaryCompletionDateStruct date: 2024-02-01, completionDateStruct date: 2024-02-15, studyFirstPostDateStruct date: 2024-03-22, lastUpdatePostDateStruct date: 2024-03-22, sponsorCollaboratorsModule leadSponsor name: Saglik Bilimleri Universitesi, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to compare the clinical success of theracal pt, therabase, and biodentine indirect pulp capping on primary molars with deep dentin caries. Indirect pulp capping was used on the primary molars of the participants with deep dentin caries. It is aimed to compare the success of biodentine, which is considered the gold standard used in capping treatments, and the currently marketed Teracal PT and Therabase materials after 1, 6 months and 1 year, with biodentine and with each other, and find out which material is more successful., conditionsModule conditions: Dentin, Carious, conditions: Indirect Pulp Capping, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Indirect pulp capping will be applied to primary molar teeth with deep dentin caries in 3 groups with 3 different materials(biodentine, thermal pt, therabase)., primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, maskingDescription: patients and the researcher who evaluates the follow-up results of the patients will not know which material was used for indirect pulp coating., whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 76, type: ACTUAL, armsInterventionsModule interventions name: indirect pulp capping with theracal pt, interventions name: indirect pulp capping with therabase, interventions name: indirect pulp capping with biodentine, outcomesModule primaryOutcomes measure: successful completion of research, primaryOutcomes measure: unseccessful completion of research, eligibilityModule sex: ALL, minimumAge: 5 Years, maximumAge: 9 Years, stdAges: CHILD, contactsLocationsModule locations facility: Sağlık Bilimleri Üniversitesi, city: Istanbul, country: Turkey, geoPoint lat: 41.01384, lon: 28.94966, hasResults: False
protocolSection identificationModule nctId: NCT06325527, orgStudyIdInfo id: YuGarden-01, briefTitle: Cognitive Impairment Cohort Study of the Elderly Population in YuGarden, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2031-04-01, completionDateStruct date: 2031-06-01, studyFirstPostDateStruct date: 2024-03-22, lastUpdatePostDateStruct date: 2024-03-22, sponsorCollaboratorsModule leadSponsor name: Ruijin Hospital, class: OTHER, descriptionModule briefSummary: The goal of this prospective observational research with an 8-year follow-up is to study the cognitive changes in the elderly in YuGarden community, Shanghai, China.The main questions it aims to answer are:* incidence of cognitive impairment in community (converting to mild cognitive impairment or Alzheimer's disease)* to build a predictive model for the progression of cognitive impairment, conditionsModule conditions: Alzheimer Disease, conditions: Neurodegenerative Diseases, conditions: Cognitive Impairment, conditions: Mild Cognitive Impairment, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 1872, type: ESTIMATED, outcomesModule primaryOutcomes measure: Incidence of cognitive impairment, secondaryOutcomes measure: The change of Mini-Mental State Examination (MMSE), secondaryOutcomes measure: The change of Barthel Index for Activities of Daily Living (ADL), secondaryOutcomes measure: The change of blood biomarkers, secondaryOutcomes measure: The change of urine biomarkers, secondaryOutcomes measure: The change of feces biomarkers, secondaryOutcomes measure: The change of gingival crevicular fluid biomarkers, secondaryOutcomes measure: The change of electroencephalogram (EEG), secondaryOutcomes measure: The change of speech information, secondaryOutcomes measure: The change of structural MRI, secondaryOutcomes measure: The change of functional MRI, secondaryOutcomes measure: The change of magnetic susceptibility, secondaryOutcomes measure: The change of perfusion MR imaging, secondaryOutcomes measure: Positron emission tomography (PET), eligibilityModule sex: ALL, minimumAge: 60 Years, maximumAge: 85 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, city: Shanghai, state: Shanghai, country: China, contacts name: Jinwen Xiao, role: CONTACT, phone: 13917310784, email: jw_xiao78@163.com, contacts name: Gang Wang, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False
protocolSection identificationModule nctId: NCT06325514, orgStudyIdInfo id: NA2024, briefTitle: Artificial Intelligence Based Program to Classify Oral Cavity Findings Based on Clinical Image Analysis, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2024-08-01, completionDateStruct date: 2024-09-01, studyFirstPostDateStruct date: 2024-03-22, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: Cairo University, class: OTHER, descriptionModule briefSummary: This study aims to develop an AI program that can classify oral findings into Normal/variation of normal or an oral disease by clinical photos analysis, aiding in lowering the percentages of false positive and false negative diagnosis of oral diseases., conditionsModule conditions: Oral Cancer, conditions: Oral Lichen Planus, conditions: Fordyce Granule, conditions: Leukoplakia, conditions: Erythroplakia, conditions: Leukoedemas, Oral, conditions: Lichenoid Reaction, designModule studyType: OBSERVATIONAL, designInfo observationalModel: ECOLOGIC_OR_COMMUNITY, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 241, type: ESTIMATED, armsInterventionsModule interventions name: Artificial intelligence based program, outcomesModule primaryOutcomes measure: risk stratification, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False